Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cetirizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | TEK | Q02763 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | DRD4 | P21917 | 1/20 | 0.74 |
| ▸ | HTR7 | P34969 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cetirizine SCHEMBL13724610 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Levocetirizine SCHEMBL5935097 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Levocetirizine SCHEMBL4914 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL2455487 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL4176 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL6474316 | 0.99 | DRD3 (0.98) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL2430457 | 0.99 | DRD3 (0.98) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL41107 | 0.99 | HRH1 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Levocetirizine SCHEMBL2255374 | 0.99 | HRH1 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL5520719 | 0.99 | HRH1 (1.00) | DRD3HRH1USP2HRH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | claimed |
| US-20260007621-A1 | Pharmaceutical Combinations for Treatment | MFS Pharmaceuticals Ltd. (AU) | 2026-01-08 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| CN-118975972-A | Gastric retention system for sustained release of therapeutic agents and methods of use thereof | 林德拉治疗公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240327353-A1 | Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Inverse Agonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-10-03 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117730073-A | Serotonin 5-HT2A, 5-HT2B and 5-HT2C receptor inverse agonists | 东北大学 | 2024-03-19 | — | — | CN | disclosed |
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230142221-A1 | COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR | MUBARAK KAMAL KHAN (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142221-A1 | COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR | MUBARAK KAMAL KHAN (US) | 2023-05-11 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-7199241-B1 | Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide | UCB, S.A. (BE) | 2007-04-03 | — | — | US | disclosed |
| US-6977301-B1 | Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide | UCB, S.A. (BE) | 2005-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327353-A1 | Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Inverse Agonists | HTR2C, HTR2A, HTR2B | HRH1 549/4885DRD3 66/4885USP2 1110/4885 |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | HRH1 4112/4885DRD3 4472/4885USP2 1372/4885 |
| US-20260007621-A1 | Pharmaceutical Combinations for Treatment | CYP3A43, CYP3A5, CYP2F1 | HRH1 52/4885DRD3 2790/4885USP2 3753/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | HRH1 4112/4885DRD3 4472/4885USP2 1372/4885 |
| US-20230142221-A1 | COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR | ACE2, ACE, AGTR2 | HRH1 2618/4885DRD3 4681/4885USP2 483/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | HRH1 1405/4885DRD3 2551/4885USP2 1175/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | HRH1 2201/4885DRD3 3138/4885USP2 2191/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | HRH1 973/4885DRD3 4085/4885USP2 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.